Atrium Therapeutics Secures $50 Million in Private Placement

The company finalized a securities-purchase agreement to issue approximately 5.17 million common shares alongside 1.13 million pre-funded warrants, each priced at $7.93. Institutional backing for the round includes Sirenia Capital Management, Aberdeen Investments, Montanova, Sessa Capital, and Casdin Capital.

Management intends to funnel the net proceeds into the development of its two primary product candidates and ongoing research initiatives. The remaining capital is earmarked for working capital and general corporate needs, providing a financial cushion for a pipeline that has struggled to maintain investor confidence throughout 2024.